The art of investing
in the science of life

The art of investing
in the science of life

SCROLL DOWN

Ally Bridge Group (ABG) is a global healthcare investment firm focused on high-impact life science innovation, across both private and public markets.

Founded in 2013 and with its investment headquarter in New York, ABG has been a proven capital and strategic partner to over 75 medical technology and biotechnology companies. Our focus is simple – investing in first-in-class and best-in-class innovations focused on improving the lives of patients…globally.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Learn More

2013

Year Founded

75+

Healthcare Investments

25

Exits by IPO or M&A

$4B

Capital Realized

WHO WE ARE

Ally” and “Bridge” for Life Science companies

Global Reach & Our Network

Harnessing global network with deep local insights, we identify and secure high-impact, transformative innovations shaping the future of life sciences.

Proven Strategic Partner

Empowering and guiding companies with strategic capital, scientific acumen, and business support to transform innovative breakthroughs into world-changing solutions for patients worldwide.

 

Deep Domain Expertise

Leveraging in-depth & decades of knowledge across medtech and biotech, swiftly transitioning late-stage investments to successful exits with unique synergies bridging our public and private equity arms.

Investing with Impact

Partner with proven management teams and the very best technologies with the potential to treat the previously untreatable and transform lives for the better.

Scientific & Investment Expertise

Dedicated in-house scientific expertise with an entrepreneurial and business builder mindset. Actively engaged in the success of our partners, with a voice across clinical, regulatory, commercial, and capital markets strategies.

Our portfolio

Latest News & Insights

Jul 30 2014
NEWPORT BEACH, Calif., July 30, 2014 – Cold Genesys, Inc. (“CGI”), a clinical-stage biopharmaceutical company developing oncolytic immunotherapies…
Read more
Dec 30 2014
Menlo Park, California, December 30, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways…
Read more
Apr 04 2016
HONG KONG, April 4, 2016 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border healthcare-focused investment group, is pleased to announce…
Read more